UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C.  20549

                           FORM 10-QSB


[X]     QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
        ACT OF 1934

             For quarterly period ended June 30, 2003

[ ]     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
        EXCHANGE ACT OF 1934


                  Commission File No.  000-30991

             SKINOVATION PHARMACEUTICAL INCORPORATED
   (Name of small business issuer as specified in its charter)


        NEVADA                                              87-0458170
(State of incorporation)                 (I.R.S.  Employer Identification No.)

                      2157 S. Lincoln Street
                    Salt Lake City, Utah 84106
                          (801) 323-2395
  (Address and telephone number of principal executive offices)

Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes [X]   No [  ]

As of July 28, 2003, the issuer had a total of 708,000 shares of common stock
issued and outstanding.

Transitional small business disclosure format:  Yes [ ]  No [X]
<PAGE>

                        TABLE OF CONTENTS

                  PART I: FINANCIAL INFORMATION

Item 1:  Financial Statements......................................3

Item 2:  Plan of Operations........................................8

Item 3:  Controls and Procedures...................................9

                    PART II: OTHER INFORMATION

Item 6:  Exhibits and Reports on Form 8-K..........................9

Signatures.........................................................9





                 PART I:   FINANCIAL INFORMATION


ITEM 1: FINANCIAL STATEMENTS

     The financial information set forth below with respect to our statements
of operations for the three and six month periods ended June 30, 2003 and 2002
is unaudited.  This financial information, in the opinion of management,
includes all adjustments consisting of normal recurring entries necessary for
the fair presentation of such data.  The results of operations for the six
month period ended June 30, 2003, are not necessarily indicative of results to
be expected for any subsequent period.




                                2

<PAGE>









             Skinovation Pharmaceutical Incorporated
                       Financial Statements
                          June 30, 2003









                                3



<PAGE>






             Skinovation Pharmaceutical Incorporated
                  (A Development Stage Company)
                          Balance Sheets



                           ASSETS
                                                      June 30,   December 31,
                                                        2003         2002
                                                   ------------- -------------
                                                    (Unaudited)

CURRENT ASSETS                                     $          -  $          -
                                                   ------------- -------------

  TOTAL ASSETS                                     $          -  $          -
                                                   ============= =============


               LIABILITIES AND STOCKHOLDER' EQUITY

CURRENT LIABILITIES

Accounts Payable - Related party                   $     33,776  $     33,776
                                                   ------------- -------------

  Total Liabilities                                      33,776        33,776
                                                   ------------- -------------

STOCKHOLDERS' EQUITY

Common Stock, $.001 par value; 50,000,000 shares
  authorized; 708,000 shares issued and outstanding         708           708

Additional Paid in Capital                               25,148        25,148

Deficit Accumulated During the Development Stage        (59,632)      (59,632)
                                                   ------------- -------------

  Total Stockholders' Equity                            (33,776)      (33,776)
                                                   ------------- -------------

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY       $          -  $          -
                                                   ============= =============





                                4

<PAGE>
<TABLE>
<CAPTION>


                    Skinovation Pharmaceutical Incorporated
                         (A Development Stage Company)
                            Statement of Operations
                                  (Unaudited)
                                                                                         From
                                                                                         Inception on
                             For the        For the        For the        For the        January 15,
                             three months   three months   six months     six months     1988
                             ended June 30, ended June 30, ended June 30, ended June 30, to June 30,
                             2003           2002           2003           2002           2003
                             -------------- -------------- -------------- -------------- --------------
<S>                          <C>            <C>            <C>            <C>            <C>
REVENUES                     $           -  $           -  $           -  $           -  $      27,937
                             -------------- -------------- -------------- -------------- --------------
EXPENSES
  General & Administrative               -              -              -              -        124,644
                             -------------- -------------- -------------- -------------- --------------

   TOTAL EXPENSES                        -              -              -              -        124,644
                             -------------- -------------- -------------- -------------- --------------

NET LOSS BEFORE DISCONTINUED
  OPERATIONS                             -              -              -              -        (96,707)

GAIN ON DISPOSAL OF OPERATIONS           -              -              -              -         37,075
                             -------------- -------------- -------------- -------------- --------------

NET INCOME (LOSS)            $           -  $           -  $           -  $           -  $     (59,632)
                             ============== ============== ============== ============== ==============

NET LOSS PER SHARE           $           -  $           -  $           -  $           -  $       (0.17)
                             ============== ============== ============== ============== ==============
WEIGHTED AVERAGE SHARES
  OUTSTANDING                      708,000        708,000        708,000        708,000        347,027
                             ============== ============== ============== ============== ==============



                                       5
</TABLE>
<PAGE>
<TABLE>
<CAPTION>

                    Skinovation Pharmaceutical Incorporated
                         (A Development Stage Company)
                            Statement of Cash Flows
                                  (Unaudited)



                                                                                  From
                                                                                  Inception on
                                                        For the six months ended  January 15, 1988
                                                                 June 30          Through
                                                            2003           2002   June 30, 2003
                                                      ------------- ------------- ----------------
<S>                                                   <C>           <C>           <C>
Cash Flows from Operating Activities

  Net Loss                                            $          -  $          -  $    (59,632)
  Less  Non-cash Items:
   Shares issued for services                                    -             -        10,433
   Shares issued for debt payment                                -             -         1,424
   Increase in accounts payable                                  -             -        33,776
   Loss on disposal of PP&E                                      -             -         5,263
                                                      ------------- ------------- -------------

  Net Cash Provided (Used) by Operating Activities               -             -        (8,736)
                                                      ------------- ------------- -------------
Cash Flows from Investing Activities
  Cash paid for PP&E                                             -             -        (5,264)
                                                      ------------- ------------- -------------

  Net Cash Provided (Used) by Investing Activities               -             -        (5,264)
                                                      ------------- ------------- -------------

Cash Flows from Financing Activities
  Cash paid for offering costs                                   -             -        (7,000)
  Common stock issued for cash                                   -             -        21,000
                                                      ------------- ------------- -------------

  Net Cash Provided (Used) by Financing Activities               -             -        14,000
                                                      ------------- ------------- -------------

Increase (Decrease) in Cash                                      -             -             -

Cash and Cash Equivalents at Beginning of Period                 -             -             -
                                                      ------------- ------------- -------------

Cash and Cash Equivalents at End of Period            $          -  $          -  $          -
                                                      ============= ============= =============

Supplemental Cash Flow Information:
  Stock issued for debt payment                       $          -  $          -  $      1,424
  Stock issued for services                           $          -  $          -  $     10,433
  Cash Paid For:
    Interest                                          $          -  $          -  $          -
    Income Taxes                                      $          -  $          -  $          -



                                       6


</TABLE>
<PAGE>


             Skinovation Pharmaceutical Incorporated
                Notes to the Financial Statements
                          June 30, 2003


GENERAL
-------

Skinovation Pharmaceutical Incorporated (the Company) has elected to omit
substantially all footnotes to the financial statements for the six months
ended June 30, 2003 since there have been no material changes (other than
indicated in other footnotes) to the information previously reported by the
Company in their Annual Report filed on the Form 10-KSB for the twelve months
ended December 31, 2002.

UNAUDITED INFORMATION
---------------------

The information furnished herein was taken from the books and records of the
Company without audit.  However, such information reflects all adjustments
which are, in the opinion of management, necessary to properly reflect the
results of the interim period presented.  The information presented is not
necessarily indicative of the results from operations expected for the full
fiscal year.




                                7


<PAGE>

     In this report references to "Skinovation," "we," "us," and "our" refer
to Skinovation Pharmaceutical Incorporated.

                    Forward Looking Statements

     This Form 10-QSB contains certain forward-looking statements and any
statements contained in this Form 10-QSB that are not statements of historical
fact may be deemed to be forward-looking statements.  Without limiting the
foregoing, words such as "may," "will," "expect," "believe," "anticipate,"
"estimate" or "continue" or comparable terminology are intended to identify
forward-looking statements.  These statements by their nature involve
substantial risks and uncertainties, and actual results may differ materially
depending on a variety of factors, many of which are not within Skinovation's
control.  These factors include, but are not limited to, economic conditions
generally, failure by management to successfully develop business
relationships, competition within the merger and acquisitions market, and the
lack of operations.

ITEM 2:  PLAN OF OPERATIONS

     We are a development stage company with no assets, we have experienced
losses since our inception and we are dependent on financing to continue our
operations.  For the six month period ended June 30, 2003, we had no cash on
hand and total current liabilities of $33,776.  The current liabilities
reflect expenses related to our reporting obligations under the Exchange Act.
We have incurred expenses of $28,776 in prior years and during the year ended
December 31, 2002, we accrued another $5,000 related to the professional
services required to prepare our reports and the costs of filing the reports
with the SEC.  In the event we acquire a business opportunity we may incur
additional reporting expenses related to proxy or information statements we
may be required to provide to our stockholders which disclose the company to
be acquired's business operations, management and financial condition.

     We have no commitments for capital expenditures for the next twelve
months.  During the next twelve months we believe that our current cash needs
may be met by loans from our directors, officers and stockholders.  However,
these understandings are not formal agreements and therefore these persons are
not obligated to provide funds.  We may repay any loans, costs of services and
advancements with cash, if available, or we may convert them into common
stock.

     Our management intends to actively pursue business opportunities during
the next twelve months.  Based on current economic and regulatory conditions,
management believes that it is possible, if not probable, for a company like
ours, without many assets or liabilities, to negotiate a merger or acquisition
with a viable private company.  The opportunity arises principally because of
the high legal and accounting fees and the length of time associated with the
registration process of "going public."  However, should any of these
conditions change, it is very possible that there would be little or no
economic value for anyone taking over control of Skinovation. In addition, we
have not made a formal study of the economic potential of any business.  At
the date of this filing, we have not identified any assets or business
opportunities for acquisition.

     All risks inherent in new and inexperienced enterprises are inherent in
our business.  Potential investors must recognize that because of our limited
capital available for investigation and management's limited experience in
business analysis we may not discover or adequately evaluate adverse facts
about the business opportunity to be acquired.  Also, we intend to concentrate
our acquisition efforts on properties or businesses that we believe to be
undervalued or that we believe may realize a substantial benefit from being
publicly owned.  Investors should expect that any acquisition candidate may
have little or no operating history, or a history of losses or low
profitability.

     It is emphasized that our management may effect transactions having a
potentially adverse impact upon our shareholders pursuant to the authority and
discretion of our management to complete acquisitions without submitting any
proposal to the stockholders for their consideration.

     Should a merger or acquisition prove unsuccessful, it is possible that we
may decide not to pursue further acquisition activities and management may
abandon its activities and our shares would become worthless.

                                8


<PAGE>



ITEM 3: CONTROLS AND PROCEDURES

     Our President, who acts in the capacity of principal executive officer
and principal financial officer, has designed and established disclosure
controls and procedures to ensure that material information is made known to
him in a timely manner by others within the company.  Our President
reevaluated the effectiveness of these disclosure controls and procedures as
of the end of the period covered by this report and determined that there
continued to be no significant deficiencies in these procedures.

     Also, our President evaluated the design or operation of our internal
control over financial reporting which relates to our ability to record,
process, summarize and report financial information.  He did not find any
significant deficiency or material weakness which would require changes to be
made or corrective actions to be taken related to our internal control over
financial reporting.  Nor did he identify fraud that involved management or
other employees who had a significant role in our internal control over
financial reporting.


                   PART II:  OTHER INFORMATION

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

Part II Exhibits

3.1    Articles of Incorporation as amended  (Incorporated by reference to
       exhibit 3.1 of the Form 10-KSB, filed March 29, 2002)
3.2    Bylaws of Skinovation (Incorporated by reference to exhibit 3.3 of the
       Form-SB, filed July 11, 2000)
31.1   Section 302 Principal Executive Officer Certification
31.2   Section 302 Principal Financial Officer Certification
32.1   Section 1350 Certification

Reports on Form 8-K

       None.


                            SIGNATURES

     In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.


                           Skinovation Pharmaceutical Incorporated


                           /S/ John W. Peters
Date: July 30, 2003    By: ____________________________________
                           John W. Peters
                           President, Principal Executive and
                           Financial Officer, and Director



                                9